Source: BioPortfolio

Promedior: Promedior Receives Breakthrough Therapy Designation from FDA for PRM151 in Idiopathic Pulmonary Fibrosis

LEXINGTON Mass. March 26 2019 PRNewswire &8212; Promedior Inc. a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis today announced that PRM151 a novel investigational antifibrotic immunomodulator has been ...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Jason Lettmann's photo - CEO of Promedior


Jason Lettmann

CEO Approval Rating


Promedior is a clinical-stage biotechnology company that develops and commercializes novel therapeutics for the treatmen... Read more